Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.43 |
| ▸ | CDK9 | P50750 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27849940 | 0.80 | SIGMAR1 (0.44) | HRH3SIGMAR1HTR2CQDPRWNT3A | |
| SCHEMBL30851448 | 0.80 | HTR2C (0.59) | HRH3SIGMAR1HTR2CHTR2AHTR7 | |
| SCHEMBL171525 | 0.80 | SIGMAR1 (0.44) | HRH3SIGMAR1HTR2CHTR7HTR6 | |
| SCHEMBL171607 | 0.80 | HTR2C (0.59) | HRH3SIGMAR1HTR2CHTR2AHTR7 | |
| SCHEMBL1749915 | 0.80 | SIGMAR1 (0.59) | HRH3SIGMAR1HTR2CHTR2AHTR7 | |
| SCHEMBL29936063 | 0.80 | SIGMAR1 (0.44) | HRH3SIGMAR1HTR2CHTR7HTR6 | |
| SCHEMBL13490633 | 0.80 | SIGMAR1 (0.44) | HRH3SIGMAR1HTR2CQDPRWNT3A | |
| SCHEMBL10068060 | 0.80 | QDPR (0.59) | HRH3SIGMAR1HTR2CQDPRWNT3A | |
| SCHEMBL103834 | 0.80 | CCR1 (0.48) | HRH3SIGMAR1HTR2CHTR2AHTR6 | |
| SCHEMBL24968399 | 0.80 | HTR2C (0.51) | HRH3SIGMAR1HTR2CHTR6QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067417-A1 | FUSED LACTAM RING COMPOUND AND USE THEREOF | 成都赜灵生物医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119431384-A | And lactam ring compound and application thereof | 成都赜灵生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118084916-A | Tri-heterocyclic compounds and uses thereof | 成都赜灵生物医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-7973056-B2 | Triazole derivative or salt thereof | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090299071-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2128155-A1 | Triazole derivative or salt thereof | Fujifilm Finechemicals Co. Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299071-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HDAC3, JAK2, STAT3 | HRH3 762/4885SIGMAR1 601/4885HTR2C 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.